Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota.
Cystic fibrosis is often associated with intestinal inflammation due to several factors, including altered gut microbiota composition. In this study, we analyzed the fecal microbiota among patients with cystic fibrosis of 10-22 years of age, and compared the findings with age-matched healthy subjects. The participating patients included 14 homozygotes and 14 heterozygotes with the delF508 mutation, and 2 heterozygotes presenting non-delF508 mutations. We used PCR-DGGE and qPCR to analyze the presence of bacteria, archaea and sulfate-reducing bacteria. Overall, our findings confirmed disruption of the cystic fibrosis gut microbiota. Principal component analysis of the qPCR data revealed no differences between homozygotes and heterozygotes, while both groups were distinct from healthy subjects who showed higher biodiversity. Archaea were under the detection limit in all homozygotes subjects, whereas methanogens were detected in 62% of both cystic fibrosis heterozygotes and healthy subjects. Our qPCR results revealed a low frequency of sulfate-reducing bacteria in the homozygote (13%) and heterozygote (13%) patients with cystic fibrosis compared with healthy subjects (87.5%). This is a pioneer study showing that patients with cystic fibrosis exhibit significant reduction of H2-consuming microorganisms, which could increase hydrogen accumulation in the colon and the expulsion of this gas through non-microbial routes.
Centro Ricerche Biotecnologiche, Università Cattolica del Sacro Cuore, Cremona 26100, Italy.
Francesco
F
Miragoli
Centro Ricerche Biotecnologiche, Università Cattolica del Sacro Cuore, Cremona 26100, Italy.
Sara
S
Federici
Centro Ricerche Biotecnologiche, Università Cattolica del Sacro Cuore, Cremona 26100, Italy.
Susanna
S
Ferrari
Istituto di Zootecnica, Università Cattolica del Sacro Cuore, Piacenza 29122, Italy.
Andrea
A
Minuti
Centro Ricerche Biotecnologiche, Università Cattolica del Sacro Cuore, Cremona 26100, Italy.
Annalisa
A
Rebecchi
Department of Translational Medical Sciences, Section of Pediatrics, University Federico II, Naples 80131, Italy.
Eugenia
E
Bruzzese
Department of Translational Medical Sciences, Section of Pediatrics, University Federico II, Naples 80131, Italy.
Vittoria
V
Buccigrossi
Department of Translational Medical Sciences, Section of Pediatrics, University Federico II, Naples 80131, Italy.
Alfredo
A
Guarino
Centro Ricerche Biotecnologiche, Università Cattolica del Sacro Cuore, Cremona 26100, Italy marialuisa.callegari@unicatt.it.
Maria Luisa
ML
Callegari
D000293:Adolescent; D000328:Adult; D001105:Archaea / Q000145:classification / Q000235:genetics; D001419:Bacteria / Q000145:classification / Q000235:genetics; D044822:Biodiversity; D002648:Child; D003106:Colon; D003550:Cystic Fibrosis / Q000382:microbiology*; D019605:Euryarchaeota / Q000235:genetics; D005243:Feces / Q000382:microbiology; D005260:Female; D000069196:Gastrointestinal Microbiome; D006801:Humans; D007422:Intestines / Q000382:microbiology* / Q000503:physiopathology; D008297:Male; D064307:Microbiota / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D055815:Young Adult
cystic fibrosis; gut microbiota; methanogen archaea; qPCR; sulfate-reducing bacteria, DGGE-PCR